---
title: "Tigermed completes the sale of all issued share capital of Shanghai Guanho Pharmaceutical"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277609264.md"
description: "Tigermed announced that it has completed the sale of all issued shares of Shanghai Guohe Pharmaceutical Technology Co., Ltd. All the conditions precedent to the share transfer agreements have been met, and the sale will be completed on March 3, 2026. The target company and its subsidiaries will continue to operate as subsidiaries of Tigermed, and their financial performance will be consolidated into the financial statements of E Fund Group. This sale is an internal transaction and will not have a significant impact on the group's consolidated financial condition"
datetime: "2026-03-03T11:07:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277609264.md)
  - [en](https://longbridge.com/en/news/277609264.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277609264.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/277609264.md) | [繁體中文](https://longbridge.com/zh-HK/news/277609264.md)


# Tigermed completes the sale of all issued share capital of Shanghai Guanho Pharmaceutical

Zhitong Finance APP news, Tigermed (03347) announced the sale of all issued share capital of Shanghai Guanho Pharmaceutical Technology Co., Ltd. (target company). All conditions precedent set forth in the share transfer agreement have been met, and the sale will be completed on March 3, 2026, in accordance with the terms and conditions of the share transfer agreement. After the completion of the sale, the target company and its subsidiaries (collectively referred to as the "target group") will continue to be subsidiaries of the company. The financial performance of the target group will be consolidated into the financial statements of E Fund Group. As the sale is an internal transaction of the group, it will not have any significant impact on the consolidated financial position of the group

### Related Stocks

- [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/en/quote/516930.CN.md)
- [Tigermed (300347.CN)](https://longbridge.com/en/quote/300347.CN.md)
- [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/en/quote/159849.CN.md)
- [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/en/quote/159837.CN.md)
- [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/en/quote/516500.CN.md)
- [TIGERMED (03347.HK)](https://longbridge.com/en/quote/03347.HK.md)

## Related News & Research

- [Junshi Biosciences Chairman Completes RMB100 Million Shareholding Increase](https://longbridge.com/en/news/281231901.md)
- [Assessing BioArctic (OM:BIOA B) Valuation After New Lecanemab Data And Regulatory Milestones](https://longbridge.com/en/news/281644038.md)
- [Clover Biopharmaceuticals Completes Enrollment in Phase 2 Trial for Combination Respiratory Vaccines](https://longbridge.com/en/news/280923090.md)
- [22:54 ETHugel to enter ECM-based injectable market with aesthetic portfolio expansion](https://longbridge.com/en/news/281291767.md)
- [RemeGen Receives Chinese Regulatory Nod for RC288 Clinical Trial](https://longbridge.com/en/news/281458440.md)